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Introduction
The many expectations surrounding
the clinical application of pharmaco-
genetics remain mostly unfulfilled.1–3
Only a limited number of applications
have actually reached clinical prac-
tice.4 To gain insight into the reasons
behind the low level of implementa-
tion of pharmacogenetic testing in the
clinical world we have carried out a
survey on the clinical practice of two
pharmacogenetic tests in four different
European healthcare systems (the Uni-
ted Kingdom, Ireland, Germany and
The Netherlands). These were testing
for Human Epidermal Growth Factor
Receptor 2 (HER2)-overexpression and
tests for determining Thiopurine
Methyltransferase (TPMT)-activity.
HER2 was identified as a potential
monoclonal-antibody target in the
early 1980s thereafter the humanized
IgG1 monoclonal antibody ‘trastuzu-
mab’ entered clinical trials in 1992.5 In
1998 it was approved by the FDA as
‘Herceptin’, an anticancer therapy
for use in breast cancer in patients
who are HER2 positive. Commercial
tests based on immunohistochemistry
(IHC) testing and cytogenetic Fluores-
cent In-Situ Hybridization (FISH) test-
ing have also been approved by the
FDA for detection of HER2 overexpres-
sion. Herceptin was approved in
Europe in the year 2000 by the EMEA’s
centralized procedure. The availability
of commercial kits has coincided with
or even preceded the launch of Her-
ceptin in the countries studied. HER2
testing received a substantial boost
when Roche, who market Herceptin
in Europe, began to fund laboratories
to provide HER2-testing services in
large markets such as the UK and
Germany. These services made HER2
testing available free of charge for
physicians over a period of several
years while the market for Herceptin
became established.6
Thiopurine drugs such as 6-mercapto-
purine (6MP) and Azothioprine have
been used since the 1950s as immuno-
suppressants for a range of autoimmune
conditions as well as Leukaemia. Thio-
purine drug use is associated with
potentially fatal myelosuppression in
individuals who poorly metabolize the
drug. An enzyme associated with thio-
purine metabolism, named TPMT was
isolated in 1980.7 TPMT testing for
patients with acute lymphoblastic leu-
kaemia (ALL) has been provided in the
UK, Germany, The Netherlands and
Ireland as part of research programmes,
often with financial support from na-
tional cancer charities. Owing to the
small market for thiopurine drugs and
generic competition there has been little
commercial interest in TPMT testing.
The tests were selected because
they were present in all countries
studied and are among the first clinical
examples of pharmacogenetic testing.
Furthermore, they cover two impor-
tant applications of pharmacogene-
tics, that is, the identification of
good responders to reduce ineffica-
cious use (HER2 test) and the preven-
tion of adverse effects by identification
of poor metabolizers (TPMT test).8–10
The study of clinical use of pharma-
cogenetics in these four countries is
part of a wider ongoing project to
assess the current European ‘state-of-
the-art’ in pharmacogenetics being
carried out by one of the institutes
of the European Commission’s Joint
Research Centre.11
In order to understand the range
and extent of factors influencing the
implementation of HER2 and TPMT
testing, our survey targeted relevant
sites (e.g. Oncology and Haematology
departments, Breast Cancer clinics and
Paediatric hospitals) to request infor-
mation addressing several dimensions
of the clinical practice of these tests.
This includes possible infrastructural,
financial, perceptional, educational,
social and legal barriers for implemen-
tation. The measure of the level of
implementation within the responder-
group was based upon the consistency
of use, measured as the percentage of
patients actually tested before they
receive treatment.
Results
Rate of response to the survey
The sample surveyed consisted of
407 physicians in four countries. We
attempted to include as many relevant
hospitals and clinics as possible in
each country, by means of contacting
local networks. A total of 111 respon-
ses were obtained from physicians
including both those that completed
the questionnaire and those that res-
ponded saying they do not perform
the test (Table 1).
This gives a total response rate of
27% (Germany 24%, UK 31%, Nether-
lands 33% and Ireland 7%). In total,
we obtained 71 completed question-
naires for HER2 and 16 for TPMT
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testing; this lower number is consis-
tent with the lower usage of TPMT
testing overall. Only one response
was obtained from Ireland so this
country has been excluded from
further analysis.
Levels of implementation
Of the 77 HER2 respondents, 8% give
treatment with trastuzumab without
any testing, and another 8% use the
test, but do not test all patients who
receive the treatment.
Of all 34 respondents who treat with
thiopurine drugs, 53% give treatment
without prior use of a pharmacoge-
netic test and a further 35% do use the
test, but do not test all patients who
receive the treatment.
The actual levels of committed,
consistent use (implementation) are
84% for HER2 testing and 12% for
TPMT testing according to our survey.
Significant differences in implementa-
tion between countries were not ob-
served.
Infrastructural barriers
In the delivery of pharmacogenetic
testing to the patient, communication
with the laboratory undertaking the
testing procedures is important for
transferring of information.12 Other
possible barriers to consider are the
sending and storage of the sample, the
so-called physical infrastructure as-
pects. As shown in Table 2, problems
with laboratory communication vary
by country. The UK respondents using
HER2 tests have significantly more
problems with their laboratory com-
munication, whereas Dutch hospitals
perceived the least problems in HER2
testing.
Financial barriers
Cost is a common barrier to the
application of novel medical technol-
ogies, and indeed in our survey, costs
were seen as a problem for both HER2
and TPMT tests (Table 2).
A physician could perceive a test as
cost-beneficial, but it is also important
to see whether calculations have actu-
ally been made. For this reason, both
perceived and calculated cost/benefit
ratio were included in the survey.
Subjects were not asked about the
methodology used to make their cal-
culations. The survey shows that HER2
testing is perceived as having more
benefits than costs (Figure 1). UK has
the most positive perception on HER2
testing and the Netherlands the least
positive. Out of all respondents, 13%
for HER2 and 20% for TPMT had made
calculations about the cost/benefit
ratio. The outcome led to a slightly
more negative cost–benefit than the
perceived cost/benefit ratio (Figure 1).
Larger hospitals and departments with
a higher percentage of doctors with
recent education have made calcula-
tions more often (data not shown).
Reimbursement of the costs is extre-
mely important: one laboratory in
the Netherlands pointed towards the
fact that they do not carry out TPMT
testing routinely because reimburse-
ment has not been arranged yet.
Similarly in the UK no NHS reimburse-
ment is available and testing is cur-
rently provided with research funding.
The respondents were not consistent
in answering the questions with dis-
agreement in responses over whether
or not reimbursement was available.
The highest consensus was reached
among the HER2 respondents from UK,
of whom the majority (73% for public
and 80% for private insurance) an-
swered that the test is fully reimbursed.
Furthermore, 80% of these UK respon-
dents agreed that HER2 testing is a
requirement for reimbursement of tras-
tuzumab. In Germany and The Nether-
lands, the consensus about full
reimbursement and requirement (for
public and private insurance) was be-
tween 50 and 60% for these topics and
thus less clear. For TPMT, the number of
cases was too low to draw conclusions.
Perception barriers
The therapeutic advantage, that is, the
clinical utility, is probably one of the
most important aspects in ensuring the
success of a medical innovation. As can
be seen in Figure 2, the clinical utility is
perceived by the majority of respon-
dents as quite high or very high for
HER2 testing. For TPMT testing, the
clinical utility is perceived by
the majority of respondents as quite
high (50%), but certain proportions
also perceive these as quite or very low
(12 and 13%). There seems to be a larger
consensus on the clinical utility of
HER2 testing when compared with
TPMT testing. An obvious reason for
this could be the presence of the Red
blood cell counting (RBC) alternative
for TPMT testing. Several respondents
explained that they do not use the
genetic test, because research is ongoing
to determine whether genotypic or
phenotypic methodologies should be
used and which is the more suitable. As
Table 1 The response to the survey on the implementation of HER2 and TPMT
testing
Country Number responded Using test Not using test at present
HER2
UK 17 15 2
D 36 36 0
NL 23 19 4
IR 1 1 0
Total 77 71 6
TPMT
UK 20 6 14
D 12 9 3
NL 2 1 1
IR 0 0 0
Total 34 16 18
Total 111 87 24
A significantly higher number of MDs responded to the HER2 questionnaire compared to the TPMT
questionnaire. More than half of the TPMT response comes from departments where the testing could
potentially be done, though indicating that they do not test at present. From this, the higher degree of
implementation of HER2 above TPMT can be seen.
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a consequence, the monitoring of the
RBCs is often done anyway, which
lowers the relevance of the genetic test.
Knowledge barriers
An appropriate level of education is
necessary for users to adequately use a
new medical technology, and genetics
is no exception.13 Whether or not the
MDs have difficulties interpreting the
results of the tests can be a good
indicator of a further need for specific
education.12 In each country, between
16 and 20% of respondents consider
the interpretation of HER2 results
to be ‘difficult’, and less than 11%
consider the interpretation of TPMT
results difficult.
Knowledge about the existence of
the tests is not always sufficient either.
Roche held an intensive campaign to
promote the use of the HER2-test with
trastuzumab treatment.6 Such a cam-
paign has never been held for TPMT.
As one of the Dutch respondents
mentioned: ‘I am not sure what to do
with TPMT testing. We receive thio-
purines from our pharmacy, and if any
testing would be necessary we assume
that our pharmacy will tell us’.
Social barriers
Public acceptance is not the strongest
determinant of implementation effec-
tiveness, but the absence of it could
certainly lead to failure. Although the
use of genetic tests in medicine is
broadly accepted by the public in
Europe,14 we have tried to investigate
whether there is public/patient resis-
tance to pharmacogenetic test use.
According to the respondents, pa-
tients are sometimes a bit worried
about the test results but this could
be because of its implications for their
treatment and they hardly ever refuse
a test.
Owing to the nature of genetic tests
gaining proper informed consent is of
great importance. However, survey
results indicate that informed consent
is not always requested by physicians
using pharmacogenetics in practice
and very few departments reported
informed consent as a significant
burden (Table 2).
Most of the physicians believed that
patient organizations have a positive
attitude towards HER2 testing. In the
case of TPMT, most physicians think
that patient organizations have a neu-
tral attitude. From this information,
no specific social issues appear, but
patient interviews are needed to gain
more insight in the situation.
Legal barriers
There is no regulatory framework
imposing consistency of testing. One
legal aspect that is often mentioned in
literature is the prevention of liability
issues by means of pharmacogenetic
testing.15 Fear of liability is likely to
increase uptake of a pharmacogenetic
test as a technology that helps to
protect doctors from litigation.16 One
respondent from Germany had a clear
opinion on the liability issue: Most
clinicians prescribing azathioprine are
getting more and more aware of the
fact that if they prescribe thiopurines
to a TPMT non-metabolizer and that
patient develops a severe adverse
reaction, the clinician will be held
responsible.
Table 2 Occurrence of possible barriers for HER2 and TPMT testing is investigated,
though the response for the TPMT case was too low to draw conclusions
Possible barrier Hospitals in which a barrier has been
perceived (number and %)
For HER2 For TPMT
Costs
UK 9 (60 %) 0 (0 %)
D 19 (54 %) 5 (55 %)
NL 9 (47 %) NDa
Storage of the sample
UK 3 (20 %) 0 (0 %)
D 8 (23%) 2 (22 %)
NL 1 (5 %) ND
Sending of the sample
UK 9 (60 %) 1 (17 %)
D 6 (17 %) 2 (22 %)
NL 2 (11 %) ND
Communication with laboratory
UK 8 (53 %) 1 (17 %)
D 11 (31 %) 3 (33 %)
NL 3 (16 %) ND
Testing capacity of the laboratory
UK 7 (47 %) 0 (0 %)
D 7 (20 %) 2 (22 %)
NL 3 (16 %) ND
Reluctance of employees
UK 2 (13 %) 1 (17 %)
D 3 (9 %) 1 (11 %)
NL 2 (11 %) ND
Asking for informed consent
UK 1 (7 %) 0 (0 %)
D 2 (6 %) 2 (22 %)
NL 0 (0 %) ND
The left-hand column, however, shows how the technical infrastructure is often problematic as regards means
of communication, sending of samples to laboratories and the storage of these samples. These are most
problematic in the UK. Cost is also reported as being a barrier for the use of testing.
aND¼not determined, owing to low representation in the sample.
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In our survey, 38% of the HER2
respondents think that pharmacoge-
netic testing prevents liability issues
and 11% think this is not the case.
A higher percentage (50%) of TPMT
respondents believe that pharmacoge-
netic testing prevents liability issues
whereas 12% believe this is not the
case. The remaining respondents do
not express a specific opinion on this.
Another legal factor that may sup-
port implementation of pharmacoge-
netic testing is regulatory requirement
of the test.
Conclusions
The clinical implementation of the
two tests studied is incomplete. HER2
reaches much higher levels (84%) than
TPMT testing (12%). This difference is
reflected in a proportionally lower
response rate for the TPMT case as
well. Although most TPMT respon-
dents perceive fewer barriers than
HER2 respondents, the requirement
in the drug label for HER2 and the
presence of a phenotypic alternative
for TPMT testing (monitoring with
RBC count) could be reasons for
the difference in implementation
degree.
The quality of technical infrastruc-
ture aspects influences the clinical
uptake. Respondents reported that
sending of samples can sometimes
be problematic in testing and that
communication with the laboratory
and the capacity of the testing labora-
tory are not always sufficient. Indeed,
failure to have a protocol for the
processing of samples for genetic
tests has been reported elsewhere as
a significant implementation pro-
blem.17
Costs are perceived as high and test
users report costs as remaining proble-
matic. This is an interesting finding
considering that both HER2 and TPMT
testing are reported as cost-effective in
a number of cost–benefit exercises.18,19
Certainly, this highlights a problem in
that costs and benefits may be accru-
ing to different parts of the healthcare
system, thus it might be that policies
are needed to incentivise physicians
to use pharmacogenetics where this
is rational for the health system as
a whole, even when this may be
more expensive for the individual
departments that request tests. Posi-
tive cost–benefit studies are not suffi-
cient for pharmacogenetic tests to
become widely used.
Clear utility of the tests is obviously
important. The majority of respon-
dents perceive the clinical utility of
HER2 and TPMT testing as high or
quite high, although only the HER2
respondents think that the benefits
clearly outweigh the costs. This could
be an explanation for the higher level
of implementation of HER2 testing,
and implies that lower awareness of
the cost benefits of using TPMT testing
may form a barrier for TPMT testing.
The use of RBC may also provide a
disincentive for physicians to use
TPMT testing.
Lack of specialized education of the
physicians could be interfering with
Figure 1 The way in which the HER2 test users perceive the cost/benefits ratio is clearly more
positive than for TPMT users. A significant part of the latter even considers the costs of TPMT
testing much higher than the benefits. As appears from the lower part of the figure, the outcomes
of calculated cost/benefit ratios vary strongly, which stresses the need for standardized
calculation methods.
Figure 2 The perceived clinical utility is clearly lower for TPMT than for HER2, which could be
one of the explanations for the lower implementation of TPMT testing.
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the clinical use of pharmacogenetics.
About one-fifth of the respondents
consider the interpretation of HER2
test results as difficult. This is a worri-
some result, as two-third of the res-
pondents claim to have had additional
courses or training and indeed the
company distributing the test held
an intensive informative campaign.
TPMT respondents however appear to
have fewer difficulties with the inter-
pretation and less courses or training,
though, at the same time, a number of
respondents were not aware of the
existence of the test.
No social barriers have been repor-
ted, and HER2 testing is even reported
as being encouraged by patient orga-
nizations. Issues related to insurance,
on the other hand, are seen as possibly
inhibiting. There were great inconsis-
tencies in the answers related to re-
imbursement procedures. This could
either mean that it is unclear to them
or that there are large differences
between insurance companies. In any
case, lack or difficulty of reimburse-
ment becomes a strong barrier for
implementation, as some of the res-
ponders admitted. On the other hand,
reimbursement could be used to posi-
tively influence the clinical uptake if
its use becomes a requirement for
reimbursement, as with HER2 testing.
The consequences for a patient who
is not tested before treatment with
thiopurine drugs could be life threa-
tening, and that might be why half of
the people surveyed pinpointed to
liability issues in TPMT testing. A
higher percentage of TPMT users think
that testing helps in preventing liabili-
ty issues. Even though this should have
a driving influence, the possibility of
phenotypic monitoring through RBC
count may reduce the drive to imple-
ment TPMT pharmacogenetic testing.
Materials and methods
The survey was sent out by e-mail. A
mailing list of physicians and heads
of departments who were possibly in-
volved in HER2-or TPMT-testing was
compiled for the countries targeted by
the survey: UK, Ireland, Germany and
The Netherlands. The aim was to reach
as many involved physicians as possi-
ble, as no data on pharmacogenetic test
use is publicly available. The question-
naire covered the level of implement-
ation and possible barriers in the
implementation: economic barriers
and reimbursement, technical barriers,
educational, social and legal barriers.
Subjects were asked to complete the
questionnaire in their own language or
give their view on the topic. Subjects
were given 2 weeks for submission and
two reminders were sent afterwards.
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